KRAS and familial pancreatic carcinoma: Bournet et al., in the study, observed no difference in OS among the mutant (8 months; 95% confidence interval (95% CI: 8.7–12.3) and WT KRAS (9 months; 95% CI: 8.7–12.8; hazard ratio HR: 1.03; p = 0.82) in advanced pancreatic cancer patients [127].